Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Chimerix, Inc. CMRX | Opaleye Management Inc. | 3,956,500 6.320% | 813,600 (+25.89%) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | Opaleye Management Inc. | 3,171,800 4.940% | 171,400 (+5.71%) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Adamas Pharmaceuticals, Inc. ADMS | Opaleye Management Inc. | 1,487,800 5.220% | 61,800 (+4.33%) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Harrow Health, Inc. HROW | Opaleye Management Inc. | 3,065,416 11.910% | 3,065,416 (New Position) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Cardiff Oncology, Inc. CRDF | Opaleye Management Inc. | 1,662,500 4.710% | 414,500 (+33.21%) | Filing History |
| 2021-02-12 5:20 pm Sale | 2020-12-31 | 13G | Avenue Therapeutics, Inc. ATXI | Opaleye Management Inc. | 0 0.000% | -920 (Position Closed) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Fortress Biotech, Inc. FBIO | Opaleye Management Inc. | 259,167 4.150% | 4,160 (+1.63%) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | TRACON Pharmaceuticals, Inc. TCON | Opaleye Management Inc. | 125,919 17.040% | 125,919 (New Position) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | FS DEV CORP COM FSDC | Opaleye Management Inc. | 704,400 5.630% | 36,000 (+5.39%) | Filing History |
| 2021-02-12 5:20 pm Sale | 2020-12-31 | 13G | Semler Scientific, Inc. SMLR | Opaleye Management Inc. | 290,500 4.360% | -43,000 (-12.89%) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Ocular Therapeutix, Inc. OCUL | Opaleye Management Inc. | 6,510,000 8.650% | 1,384,000 (+27.00%) | Filing History |
| 2021-01-08 5:28 pm Purchase | 2020-12-30 | 13G | FS DEV CORP COM FSDC | Opaleye Management Inc. | 668,400 5.340% | 668,400 (New Position) | Filing History |
| 2020-09-25 5:20 pm Sale | 2020-09-24 | 13D | Protara Therapeutics, Inc. TARA | Opaleye Management Inc. | 2,508,472 23.860% | -2,527,538 (-50.19%) | Filing History |
| 2020-09-18 6:48 pm Purchase | 2020-09-09 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | Opaleye Management Inc. | 3,000,400 5.100% | 3,000,400 (New Position) | Filing History |
| 2020-08-31 9:40 pm Purchase | 2020-08-27 | 13G | TRACON Pharmaceuticals, Inc. TCON | Opaleye Management Inc. | 85,917 13.030% | 85,917 (New Position) | Filing History |
| 2020-08-28 5:15 pm Purchase | 2020-08-19 | 13G | Cardiff Oncology, Inc. CRDF | Opaleye Management Inc. | 1,248,000 5.370% | 1,248,000 (New Position) | Filing History |
| 2020-08-21 5:15 pm Purchase | 2020-08-11 | 13G | Adamas Pharmaceuticals, Inc. ADMS | Opaleye Management Inc. | 1,426,000 5.040% | 1,426,000 (New Position) | Filing History |
| 2020-08-21 4:30 pm Purchase | 2020-08-13 | 13G | Chimerix, Inc. CMRX | Opaleye Management Inc. | 3,142,900 5.140% | 3,142,900 (New Position) | Filing History |
| 2020-05-26 11:09 am Purchase | 2020-05-14 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 2,625,000 10.270% | 285,000 (+12.18%) | Filing History |